Positive data from the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 study, presented at ECTRIMS congress, supports the use of Sativex® to reduce symptoms of moderate to severe spasticity due to multiple sclerosis (MSS) · The new study data shows that, after three months, 41% of patients treated with Sativex®, who were resistant to other therapies, showed a clinically relevant effect · The medicine has proven to be a cost effective treatment in Germany where Almirall has already made it available as well as in Spain and Denmark Slowly but surely (SATIVEX) use is spreading across the globe Frank
